{"nctId":"NCT01301183","briefTitle":"Effects of Anorexia Nervosa on Peak Bone Mass","startDateStruct":{"date":"2011-02","type":"ACTUAL"},"conditions":["Anorexia Nervosa"],"count":75,"armGroups":[{"label":"Rh IGF-1 + Transdermal estradiol","type":"EXPERIMENTAL","interventionNames":["Drug: RhIGF-1 with transdermal 17-beta estradiol"]},{"label":"Placebo + Transdermal estradiol","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo and transdermal 17-beta estradiol"]}],"interventions":[{"name":"RhIGF-1 with transdermal 17-beta estradiol","otherNames":["Mecasermin and Vivelle Dot patch"]},{"name":"Placebo and transdermal 17-beta estradiol","otherNames":["Vivelle Dot patch"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: AN:\n\n* Age: 14-22 years old\n* Bone age (BA): ≥14 years\n* Should meet DSM IV criteria for AN\n* Subjects at MGH will be evaluated by co-investigator Dr. David Herzog, Director of the Harris Center for Eating Disorders, at MGH, and by Dr. Debra Katzman, co-investigator, and the Hospital for Sick Children, Toronto who directs their Eating Disorders Program, respectively, before enrollment.\n\nInclusion Criteria: Controls:\n\n* Healthy adolescent girls 14-22 years\n* BA of ≥14 years\n* BMI between the 10th-90th percentiles for age\n* Regular menstrual periods every 28-35 days for subjects ≥ 2 years post-menarche.\n\nExclusion Criteria:\n\n* Diseases known to affect bone metabolism including untreated thyroid disease, Cushing's syndrome, diabetes, pituitary disease, renal failure and prior bone fracture within six months of the study.\n* Medications known to affect bone metabolism, including gonadal steroids, within three months.\n* Evidence of suicidality, psychosis, or substance abuse.\n* Premature ovarian failure, as demonstrated by an elevated FSH.\n* Abnormal TSH.\n* Hematocrit \\<30%, Potassium \\<3.0 mmol/L, Glucose \\<50 mg/dl\n* Pregnancy\n* History of malignancy\n* Contraindications to estrogen therapy (for girls with AN)","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"14 Years","maximumAge":"22 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Bone Density Over a 12-month Period","description":"Change in lumbar spine BMD z-score over 12 months as assessed by dual energy x-ray absorptiometry (DXA) The z-score indicates the number of standard deviations that BMD is away from the mean for age, sex and race. A z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher values. A positive change in z-scores indicates a favorable outcome whereas a negative change in z-scores indicates an unfavorable outcome.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","spread":null},{"groupId":"OG001","value":"0.280","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Trabecular Number at the Ultradistal Radius Over a 12-month Period","description":"Change in trabecular number at the ultradistal radius over 12 months as assessed by high resolution peripheral quantitative computed tomography (HRpQCT)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":null},{"groupId":"OG001","value":"-0.02","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":38},"commonTop":["Headache","Vasovagal with venipuncture","Constipation","Irritation at patch site","Irregular menses"]}}}